{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:34Z","timestamp":1789997554692,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:07:26Z","timestamp":1661375246000},"page":"1272-1281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study"],"prefix":"10.1016","volume":"44","author":[{"given":"Ming-Ting","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"McGirr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Ping","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hsing","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Te","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Hsiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8805-8340","authenticated-orcid":false,"given":"Wayne Huey-Herng","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinthera.2022.08.006_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007444","article-title":"Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial","volume":"7","author":"Pol","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.clinthera.2022.08.006_bib0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.08.006_bib0003","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.clinthera.2022.08.006_bib0004","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.clinthera.2022.08.006_bib0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1567-5688(11)70886-8","article-title":"Pitavastatin: an overview","volume":"12","author":"Saito","year":"2011","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"10.1016\/j.clinthera.2022.08.006_bib0006","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erc.11.47","article-title":"Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis","volume":"9","author":"Yokote","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"14","key":"10.1016\/j.clinthera.2022.08.006_bib0007","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.clinthera.2022.08.006_bib0008","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1016\/j.clinthera.2022.08.006_bib0009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4070\/kcj.2014.44.4.227","article-title":"Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe","volume":"44","author":"Choi","year":"2014","journal-title":"Korean Circ J"},{"issue":"25","key":"10.1016\/j.clinthera.2022.08.006_bib0010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinthera.2022.08.006_bib0011","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk-factor management and use of drug therapies in coronary patients from 15 countries","volume":"22","author":"Euroaspire","year":"2001","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.clinthera.2022.08.006_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","article-title":"Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk","volume":"39","author":"Yang","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clinthera.2022.08.006_bib0013","unstructured":"2020 US FDA approved label of LIPTRUZET\u00ae."},{"key":"10.1016\/j.clinthera.2022.08.006_bib0014","unstructured":"2020 US FDA approved label of VYTORIN\u00ae."},{"key":"10.1016\/j.clinthera.2022.08.006_bib0015","unstructured":"2021 US FDA approved label of ROSZET\u00ae."},{"key":"10.1016\/j.clinthera.2022.08.006_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.clinthera.2022.08.006_bib0017","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cger.2009.07.007","article-title":"The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs","volume":"25","author":"Yazdanyar","year":"2009","journal-title":"Clin Geriatr Med"},{"issue":"6","key":"10.1016\/j.clinthera.2022.08.006_bib0018","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"issue":"2","key":"10.1016\/j.clinthera.2022.08.006_bib0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40256-016-0197-9","article-title":"Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA Study","volume":"17","author":"N\u00fa\u00f1ez-Cort\u00e9s","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"10.1016\/j.clinthera.2022.08.006_bib0020","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:39:09Z","timestamp":1778629149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002867"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}